Lyell Immunopharma (NASDAQ:LYEL) CEO Lynn Seely Sells 7,455 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely sold 7,455 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the transaction, the chief executive officer directly owned 74,266 shares of the company’s stock, valued at approximately $1,737,081.74. This represents a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Lynn Seely also recently made the following trade(s):

• On Tuesday, February 10th, Lynn Seely sold 438 shares of Lyell Immunopharma stock. The stock was sold at an average price of $23.12, for a total transaction of $10,126.56.

Lyell Immunopharma Stock Up 4.3%

Shares of LYEL traded up $1.04 during mid-day trading on Thursday, hitting $25.38. The company had a trading volume of 63,758 shares, compared to its average volume of 86,064. Lyell Immunopharma, Inc. has a 1-year low of $7.65 and a 1-year high of $45.00. The business’s 50-day simple moving average is $27.98 and its 200-day simple moving average is $19.64. The stock has a market cap of $539.07 million, a PE ratio of -1.10 and a beta of -0.14.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.81) by $0.68. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. On average, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and increased their target price for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $45.00.

Institutional Investors Weigh In On Lyell Immunopharma

A number of large investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its position in Lyell Immunopharma by 773.5% during the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after acquiring an additional 154,327 shares in the last quarter. Acadian Asset Management LLC grew its position in Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Lyell Immunopharma during the second quarter valued at approximately $258,000. Marshall Wace LLP acquired a new position in shares of Lyell Immunopharma during the second quarter worth $94,000. Finally, RBF Capital LLC purchased a new position in shares of Lyell Immunopharma in the second quarter valued at $884,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.